Alicia Gambetti
Family Medicine · Vacaville, CANPI 1164930640
Payments from drug & device makers
Across 86 payments — averaging $24.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$535
- Novo Nordisk$328
- AstraZeneca$172
- Inspire Medical Systems, Inc.$153
- Biogen$151
- Astellas Pharma US Inc$107
- plus $675 from 18 others
What the payments were for
- Food & beverage$2,119100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 32 | $535 |
| Novo Nordisk | 9 | $328 |
| AstraZeneca | 4 | $172 |
| Inspire Medical Systems, Inc. | 1 | $153 |
| Biogen | 6 | $151 |
| Astellas Pharma US Inc | 1 | $107 |
| Viiv Healthcare Company | 4 | $103 |
| GSK | 5 | $95 |
| Lilly USA, LLC | 5 | $95 |
| Dexcom, Inc. | 2 | $57 |
| Organon | 3 | $47 |
| Pfizer | 2 | $36 |
| Bayer | 1 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Hologic Sales And Service, LLC | 1 | $26 |
| Abbott | 1 | $22 |
| Gilead | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Edwards Lifesciences | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Merck | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,119 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 11 | $19,045 |
| Levothyroxine Sodium | 28 | $627 |
| Metoprolol Succinate | 24 | $435 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $434 |
| Rosuvastatin Calcium | 11 | $399 |
| Fluticasone Propionate | 17 | $347 |
| Trazodone Hcl | 24 | $328 |
| Omeprazole | 18 | $320 |
| Atorvastatin Calcium | 26 | $281 |
| Amlodipine Besylate | 25 | $277 |
| Losartan Potassium | 20 | $245 |
| Tamsulosin Hcl | 13 | $244 |
| Duloxetine Hcl | 11 | $193 |
| Metformin Hcl ErMetformin Hcl | 11 | $118 |
| Lisinopril | 13 | $106 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $328 | $19,04511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.
Other family medicine in Vacaville
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.